aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Vividion Therapeutics, founded in San Diego, focuses on developing precision therapeutics for cancers and immune disorders. The company's core mission is to utilize novel discovery technologies to unlock traditionally undruggable targets, addressing critical unmet medical needs. Vividion's innovative platform aims to expand the boundaries of druggability, offering new hope for patients who previously had limited treatment options.
Notable figures affiliated with Vividion include its team of leading scientists and industry experts dedicated to advancing its mission. The company has attracted significant investment from prominent venture capital firms and strategic partners in the biopharmaceutical industry. Key achievements include the development of a robust pipeline of potential therapies and recognition for its cutting-edge approach to drug discovery. Vividion's impact lies in its potential to transform treatment paradigms for severe diseases, offering new possibilities for patient care.
Operating Status
Acquired
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Therapeutics, Drugs
Technology
Biotech
Tags
Biotech, Healthtech
Model Types
Biotech
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Vividion Therapeutics founded?
Vividion Therapeutics was founded in 2013.
Where is Vividion Therapeutics’s headquarters located?
Vividion Therapeutics’s headquarters is located in Los Angeles, CA, US.
When was Vividion Therapeutics’s last funding round?
Vividion Therapeutics’s most recent funding round was for $135M (USD) in February 2021.
How many employees does Vividion Therapeutics have?
Vividion Therapeutics has 228 employees as of Feb 5, 2024.
How much has Vividion Therapeutics raised to-date?
As of July 05, 2023, Vividion Therapeutics has raised a total of $371.5M (USD) since Feb 24, 2021.
Add Comparison
Total Raised to Date
$371.5M
USD
Last Update Feb 24, 2021
Last Deal Details
$135M
USD
Feb 24, 2021
Series C
Total Employees Over Time
228
As of Feb 2024
Vividion Therapeutics Address
10550 N Torrey Pines Rd
Los Angeles,
California
92037
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts